Türk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - TRILUMINATE Pivotal – Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation (Dr. Mehmet Altunova)

[Türkçe]

Turkish Society of Cardiology Young Cardiologists Bulletin Year: 8 Number: 3 / 2025

Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin

Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan

Coordinator for the
Board of Directors
Dr. Can Yücel Karabay

Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı

Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Muzaffer Kahyaoğlu

Contributors
Dr. Ahmet Caner Canpolat
Dr. Aysu Oktay
Dr. Hadi Verdiyev
Dr. Kemal Göçer
Dr. Mehmet Altunova
Dr. Mehmet Murat Yiğitbaşı
Dr. Merve Kapçık
Dr. Muhammed Ali Söyler
Dr. Muhammet Ali Ekiz
Dr. Mustafa Yenerçağ
Dr. Mustafa Yılmaz
Dr. Özkan Karaca
Dr. Ramazan Furkan Demirkıran
Dr. Seda Kurat Güldoğmuş
Dr. Sefa Sarı
Dr. Selim Süleyman Sert
Dr. Serkan Bulguroğlu
Dr. Ülkü Nur Koç
Dr. Yücel Kanal

TRILUMINATE Pivotal – Transcatheter Edge-to-Edge Repair for Severe Tricuspid RegurgitationTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - TRILUMINATE Pivotal – Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation (Dr. Mehmet Altunova)

Prepared by: Dr. Mehmet Altunova

Name of the Study: TRILUMINATE Pivotal – Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation

Published in Congress: EuroPCR 2025

Link: https://www.pcronline.com/News/Whats-new-on-PCRonline/2025/ACC/Two-year-outcomes-of-transcatheter-tricuspid-valve-edge-to-edge-repair-for-tricuspid-regurgitation-The-Triluminate-pivotal-trial Introduction

In patients with symptomatic severe tricuspid regurgitation (TR) who are not candidates for surgery, transcatheter edge-to-edge repair (TEER) is increasingly considered. The TRILUMINATE Pivotal trial is the first randomized controlled study to evaluate the long-term clinical benefits and safety of TEER.

Objective

To assess the effects of TEER on mortality, heart failure hospitalization, and quality of life in patients unsuitable for surgery.

Methods

A total of 350 patients were randomized to either TEER with the TriClip device (n=175) or medical therapy (n=175). The primary endpoint was a hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalization, and improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

Results

TEER demonstrated superiority over medical therapy in the primary endpoint (p=0.02). At 30 days, 87% of patients in the TEER group had TR severity reduced to moderate or less (vs 4.8% in the medical group; p<0.001). The KCCQ score improved by an average of 12.3 points in the TEER group (vs 0.6 points in the medical therapy group; p<0.001). At 2 years, TEER reduced heart failure hospitalizations by 28%.

Conclusions

TEER appears to be a safe and effective option to improve symptoms and quality of life in high-risk patients with severe TR.

Limitations and Concerns
The study population consisted of patients unsuitable for surgery or at high surgical risk, limiting the applicability of the results to lower-risk patients. With only 350 patients enrolled, the statistical power for some secondary endpoints may be insufficient. Long-term (>2 years) durability of the valve and clinical outcomes are still unknown.

Commentary

This trial underscores the value of TEER as a strong alternative for high-risk TR patients, and longer-term data will further confirm its clinical benefits.